[{"orgOrder":0,"company":"University of California","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UC San Diego to Assess Hypertension Drug Ramipril for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ramipril","moa":"ACE","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of California","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"University.."},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"CNIC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Aspirin","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Ferrer Internacional","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ferrer Internacional \/ CNIC","highestDevelopmentStatusID":"12","companyTruncated":"Ferrer Int.."}]

Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3551

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

                          Brand Name : Polypill

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 26, 2022

                          Lead Product(s) : Aspirin,Ramipril,Simvastatin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : CNIC

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          University of California

                          Country arrow
                          Formnext Forum
                          Not Confirmed

                          University of California

                          Country arrow
                          Formnext Forum
                          Not Confirmed

                          Details : Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 01, 2020

                          Lead Product(s) : Ramipril

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank